Abstract 2927
Background
Cancer, which is included in the scope of chronic diseases, affects the lifestyle and quality of the individuals, who got diagnosed, and their familes due to the disease course and treatment method. According to the "theory of family systems", when a disease occurs in the individual, the whole family is affected by the disease, not only patient. It is suggested that families should not be seen as a passive shelter for patients, they should also as a human unity living at the same time as the cancer crisis. In cancer care, caregivers have many responsibilities, from diagnosis to the end of life. While there are studies conducted to evaluate the quality of life of cancer patients in Turkey and other countries, there are a limited number of studies evaluating the quality of life of caregivers of cancer patients. It was aimed to performed in our country for validity and reliability of "Singapore Caregiver Quality Of Life Scale", which was planned based on this deficiency, and to be a guide for the evaluation of the quality of the life of the relatives or carers of different cultures, different ethnic groups and determining the nursing care strategies.
Methods
This study, which was planned as a methodological and descriptive study, was caried out with 550 caregivers in two university hospitals in Izmir. The data were collected by using the Individual Presentation Form, Singapore Caregiver Quality of Life Scale and Quality of Life Scale in Cancer Patients Family Version. Written informed consent was obtained from hospitals and individuals.
Results
The analysis of the findings is ongoing and will be shared in the full text.
Conclusions
Quality of life of caregivers of cancer patients is an important indicator of the quality of life of the patient. In this study, Turkish validation sfudies of the "Singapore Caregiver Quality Of Life Scale" were conducted. The results will be shared later.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4290 - Characterization of the mechanism of action and efficacy of MEN1611 (PA799), a novel PI3K inhibitor, in breast cancer preclinical models.
Presenter: Alessio Fiascarelli
Session: Poster Display session 3
Resources:
Abstract
2167 - Neat-1: culprit lnRNA tying PIG-C, MSLN, CD80 in TNBC
Presenter: Nada Hussein
Session: Poster Display session 3
Resources:
Abstract
1829 - A novel RAF/MEK inhibitor CH5126766 in phase 1 clinical trial has an effectiveness in the combination with eribulin for the treatment of triple negative breast cancer
Presenter: Hisako Ono
Session: Poster Display session 3
Resources:
Abstract
4357 - Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer
Presenter: Eva Galan-Moya
Session: Poster Display session 3
Resources:
Abstract
5163 - Preclinical Evaluation targeting both IGF1R and IR in Triple Negative Breast Cancer
Presenter: Alex Eustace
Session: Poster Display session 3
Resources:
Abstract
832 - Monospecific antibody targeting of CDH11 inhibits epithelial-to-mesenchymal transition and represses cancer stem cell-like phenotype by up-regulating miR-335 in metastatic breast cancer, in vitro and in vivo.
Presenter: Jia-Hong Chen
Session: Poster Display session 3
Resources:
Abstract
3781 - Pharmacological screening with Chk1 inhibitors identify synergistic agents to overcome resistance to platinums in basal breast and ovarian cancer
Presenter: Ana Lucia Sanabria
Session: Poster Display session 3
Resources:
Abstract
3275 - Comparison of 11 circulating miRNAs and CA125 kinetics in ovarian cancer during first line treatment: data from the randomized CHIVA trial (a GINECO-GCIG study)
Presenter: Patrick Robelin
Session: Poster Display session 3
Resources:
Abstract
3391 - Inhibiting Ehmt2 and Ezh2 histone methyltransferases alters the immune microenvironment in a Trp53-/- murine ovarian cancer model
Presenter: Pavlina Spiliopoulou
Session: Poster Display session 3
Resources:
Abstract
3839 - Fenofibrate impairs pro-tumorigenic potential of cancer stem cell-like cells within drug-resistant prostate cancer cell populations.
Presenter: Tomasz Wróbel
Session: Poster Display session 3
Resources:
Abstract